SHP-1 is a key tyrosine phosphatase that acts as a negative regulator of signal transduction in lymphocytes, which has been found down-regulated in several T cell lines derived from human T cell malignancies. The standardization of a sensitive ELISA for the quantification of SHP-1 protein in peripheral T and B lymphocytes has enabled us to quantify the SHP-1 content of freshly isolated T cells from patients with Sezary syndrome and in the Sezary T cell line HUT-78. In all cases, a dramatic decrease in the content of this protein, when compared with the content in healthy volunteer controls, was observed. These results were corroborated when the expression of SHP-1 mRNA was analyzed. In order to study whether there was any correlation between SHP-1 protein expression and tyrosine phosphorylated state of JAK3, the state of phosphorylation of JAK3 was studied in the T cell line HUT-78, and found to be highly phosphorylated. These results suggest that SHP-1 might be involved in maintaining the IL-2R/JAK3 signaling pathway under control and point towards a role of SHP-1 in the pathogenesis of the disease.
Introduction
SHP-1 is an intracytoplasmic tyrosine phosphatase (PTPase), expressed almost exclusively in hematopoietic cells. 1 SHP-1 plays an important role as an inhibitory modulator of activation signals delivered through a variety of surface receptors, such as antigen receptors and coreceptors, [2] [3] [4] [5] NK inhibitory receptors 6 and cytokine and growth factor receptors. [7] [8] [9] [10] [11] [12] Focusing on T cell receptor signaling, SHP-1 negatively regulates T cell activation, 13 by interacting with ZAP-70. 14 In addition, once T cells are activated, they require a proper signaling through IL-2R in order to achieve clonal expansion and differentiation. Biochemical pathways initiated by the binding of IL-2 to the IL-2R include activation of the associated Janus kinases JAK1 and JAK3, 15 and the sequential phosphorylation of signal transducer and activator of transcription (STATs) proteins, 16 that translocate to the nucleus and initiate the transcription of IL-2-responsive genes. SHP-1 involvement in IL-2 signaling appears to be related to JAK kinase dephosphorylation, 11 although the precise molecular mechanism of SHP-1 recruitment to the IL-2R complex has not been established. A critical role of SHP-1 in hematopoietic cell behavior can be inferred from the naturally occurring SHP-1 gene-mutation responsible for the motheaten phenotype in mice, 17 that results in a profound immunological dysfunction, also manifested in the T cell lineage. 3, 13 In humans, a down-regulated SHP-1 expression has been reported under physiological conditions in B centroblasts pur- ified from germinal centers, and in their malignant counterparts from Burkitt lymphomas. 18 Also, a defective expression of SHP-1 has been documented in the myeloproliferative disorder polycythemia vera, 19 suggesting a role for SHP-1 as a negative regulator of the erythropoietin-receptor (Epo-R)/JAK2 signaling pathway. 7 A low expression of SHP-1 was initially related with HTLV-I transformed T cell lines, 11 but it has subsequently been reported in T cell lines derived from T cell lymphomas (HTLV-I positive or negative) and cutaneous T cell lymphomas (CTCL). 20 Furthermore, biochemical analyses in these T cell malignancies have demonstrated a constitutive activation of the IL-2R-mediated JAK3/STAT5 signaling pathway, 21, 22 suggesting that the lack of the negative modulator SHP-1 could result in an aberrant persistence of a proliferative signal, followed by T cell hyperplasia and/or neoplasia.
Malignant Sezary cells represent the leukemic expression of mycosis fungoides, a low grade cutaneous T cell lymphoma. 22 Although these malignant cells are typically CD4
+

CD7
Ϫ T cells, other phenotypes (ie CD4 + CD7 + ) do not exclude malignancy. An increased tyrosine-phosphorylation of JAK3 has been found in most, but not all (11 out of 14) Sezary cells isolated from patients with Sezary syndrome (SS). 21 Considering that tyrosine hyperphosphorylation of JAK3 has been associated with a down-regulated expression of SHP-1 in malignant lymphoma T cell lines, 20 we wanted to check SHP-1 expression in freshly isolated Sezary cells in order to establish a correlation between reduced SHP-1 expression and malignant leukemization of mycosis fungoides. To investigate this, we have standardized a very sensitive SHP-1 sandwich ELISA and found a decreased or undetectable SHP-1 protein expression in freshly isolated Sezary cells purified from three patients with SS. Furthermore, a low SHP-1 mRNA content and undetectable SHP-1 protein expression were found in resting HUT-78, a cutaneous T cell lymphoma line derived from a patient with SS. 23 In this line, an increased phosphorylation of JAK3 was associated with the diminished SHP-1 expression. These results suggest a possible causative role of the down-regulation of SHP-1 in this malignancy.
Materials and methods
Cell culture, flow cytometry and purification of SS cell Cell lines:
HUT-78 and Jurkat T cell lines were grown in complete RPMI 1640/10% FCS (Gibco BRL, Life Technologies, Paisley, UK). HUT-78 was obtained from ECACC, No 88041901.
Patients:
The diagnosis of SS was made based on well established clinical, histological and immunophenotypical criteria. 24, 25 Three patients with SS and severe peripheral + and CD7 Ϫ fractions were separated in patient SS-3 by coating the magnetic beads with anti-CD7 mAb (Pharmingen, San Diego, CA, USA). When indicated, either T cell lines or the patient's T cells were stimulated either with 2.5 g/ml anti-CD3 (HiT3a clone; Pharmingen) and 5 ng/ml recombinant human IL-2 (R&D Systems, Minneapolis, MN, USA), or 10 ng/ml PMA and 100 ng/ml ionomycin A (Io) (Sigma, St Louis, MO, USA), or 25 g/ml phytohemaglutinin (PHA) and 5 ng/ml recombinant human IL-2. Flow cytometric immunophenotyping was performed by direct immunostaining using FITC-or PE-labeled mAb obtained from Becton Dickinson Pharmingen, and analyzed on a standard FACScan (Becton Dickinson, San José, CA, USA).
RNA extraction and analysis of mRNA
Total cellular mRNA was isolated using the monophasic solution of phenol and guanidine isothiocyanate (Tripure Isolation Reagent; Boehringer Mannheim, Mannheim, Germany), followed by chloroform and isopropanol precipitation.
RT-PCR:
Complementary DNA (cDNA) was synthesized by reverse transcription from 1 g RNA using M-MuLV reverse transcriptase (Boehringer Mannheim) and amplified (PCR) with Taq DNA polymerase (Boehringer Mannheim) using 0.5 M primers, 200 M dNTPs in the reaction buffer supplied with the enzyme, for 35 cycles (denaturation 95°C, 1 min; annealing 65°C, 1 min; elongation 72°C, 1 min). Primers used for the specific amplification of SHP-1 and GAPDH were: SHP-1 5Ј-GAC TGT GAC ATT GAC ATC CAG-3Ј and 5Ј-CTT CCT CTT GAG GGA ACC CTT-3Ј (350 bp product), GAPDH 5Ј-TGA TGA CAT CAA GAA GGT GGT GAA GC-3Ј and 5Ј-TTA CTC CTT GGA GGC CAT GTG GGC CA-3Ј (240 bp product).
Northern blot analysis
Five to 10 g of total RNA isolated from T cell lines and T lymphocytes from SS-1 patient were separated in 1% agarose gel containing 2.2 M formaldehyde and 20 mM MOPS propanesulfonic acid, pH 6.8) and capillary blotted on to Hybond-N transfer membrane (Amersham Pharmacia Biotech, Uppsala, Sweden). Filters were hybridized in 50% formamide containing 5ϫ SSC, 10ϫ Denhardt's solution, 10% dextran sulfate, 0.1% SDS, 0.1 mg of herring sperm DNA/ml and full length SHP-1 32 P-cDNA (10 6 c.p.m./ml) labeled by random priming. Final wash of the filter was 0.2ϫ SSC, 0.1% SDS at 50°C.
Leukemia
Immunoprecipitation and Western blot analysis
For immunoprecipitation, cells were washed in PBS and lysed in lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 10 mM EDTA, 1 g/ml each leupeptin and pepstatin, 100 g/ml PMSF). Supernantants of 18 000 g were immunoprecipitated by using rabbit polyclonal IgG against JAK3 (C21, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-SHP-1 mAb 2F12 (provided by Prof RJ Matthews, University of Wales College of Medicine, Cardiff, UK) and Protein G Sepharose (Amersham Pharmacia Biotech). After washing the slurry in lysis buffer, proteins were resolved on 10% SDS/polyacrylamide gels under reducing conditions, transferred on to polyvinylidene membrane (Immobilon P; Amersham PB) and immuno-blotted with either antiserum to Jak-3 (C21), SHP-1 (rabbit polyclonal) or anti-phosphotyrosine (HRPo-RC20; Transduction Laboratories, Lexington, KY, USA).
For Western blot analysis of total cell lysates, pellets were directly lysed in gel sample buffer (1% SDS, 3% 2␤-ME, 50 mM Tris-HCl 6.8), and processed as above. Blots were visualized by enhanced chemiluminiscence (ECL plus, Amersham PB).
Quantitative ELISA for the determination of SHP-1 Materials:
Human spleens were obtained from cadaveric kidney donors; plasmid pKG-SHP-1, that contains the fulllength coding sequence of mouse SHP-1 cDNA (amino acid residues 1-595 of SHP-1), and hybridoma 2F12 cells were kindly provided by Prof RJ Matthews; Glutathione Sepharose 4B, IPTG, thrombin and Sephacryl S-300 were obtained from Pharmacia Biotech; DEAE-cellulose and DE-52 from Whatman (Clifton, NJ, USA); microELISA polystyrene plates from Nunc (Roskilde, Denmark); goat anti-rabbit IgG-HRP were from Tago (Burlingame, CA, USA). Other chemicals were from Sigma.
Expression of recombinant SHP-1:
E. coli strain TG1 was transformed with pKG-SHP-1 plasmid, induced overnight at 25°C with 0.1 mM IPTG (isopropyl ␤-D-thiogalactoside) and lysed in lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.2 mM PMSF, leupeptin 20 g/ml, 1% Triton X-100, lysozyme 10 mg/ml), followed by sonication and centrifugation at 10 000 g for 15 min at 4°C to remove the insoluble fraction.
Purification and cleavage of the GST-SHP-1 fusion protein with thrombin:
This was performed using Glutathione Sepharose 4B columns (0.5 ϫ 2 cm) (Pharmacia Biotech) according to the manufacturer's instructions. SHP-1 was separated from thrombin by Sephacryl S-300 gel filtration.
Purification of human SHP-1:
Native SHP-1 was obtained from human spleen cytosolic fraction. A piece of approximately 50 g. was homogenized with 250 ml of 10 mM phosphate buffer pH 7.4, 2 mM EDTA, 0.2 mM PMSF, 0.5 g/ml leupeptin, 0.7 g/ml pepstatin, and centrifuged at 4000 g for 15 min, followed by 15 min at 10 000 g and finally 60 min at 100 000 g. The 100 000 g supernatant was adjusted to 0.25 M NaCl and loaded on to a series of chromatography columns in tandem: DEAE-cellulose (5 ϫ 10 cm), irrelevant human IgGsepharose 4B (15 mg IgG/ml Sepharose 4B, 3 ϫ 1 cm), (these columns do not bind PTP SHP-1 under these conditions, but retain other proteins that could bind unspecifically to the anti SHP-1 affinity column), and finally anti-SHP-1-Sepharose 4B (moAb 2F12 4 mg/ml Sepharose 4B) (1 ϫ 2 cm), which had been equilibrated in 25 mM Tris-Acetate pH 7.5, 250 mM NaCl. After filtering the 100 000 g supernatant, the columns were then washed with 300 ml of the same buffer, disconnected, and the affinity anti-SHP-1 column was washed with 100 ml of the same buffer, followed by 100 ml of 25 mM TrisAcetate pH 7.5 and finally eluted with 12.5 mM Diethylamine pH 11.0. Fractions of 900 l were collected over 100 l of 500 mM Tris-Acetate pH 7.5, 2 mM EDTA, 2 mM EGTA, 0.2 mM PMSF, 0.5 g/ml leupeptin, in order to neutralize the eluted protein immediately. The purity of the protein was then checked by SDS-PAGE and Western blotting. Aproximately 0.2 mg of protein of a purity ranging from 70 to 80%, as judged by SDS-PAGE, was obtained in different preparations.
Antibodies:
Polyclonal antibody against SHP-1 was raised in rabbits in our laboratory. Hamster anti-mouse SHP-1 mAb (2F12, IgG) was purified from nude mice ascitis. In order to avoid unspecific interaction in the ELISA, the polyclonal IgG against SHP-1 was filtered through a Sepharose-moAb 2F12 and a Sepharose-human IgG column.
ELISA:
MoAb anti-SHP-1 2F12 was bound to the polystyrene microtiter plates (96 wells, Nunc Maxisorp) by incubating overnight 500 ng per well in 100 l of PBS pH 7.4 at 4°C. Prior to use, plates were washed with buffer A (PBS 0.1% Tween-20), and blocked with 200 l of buffer B (PBS, 0.1% Tween-20, 0.25% NP-40, 1% BSA) for 30 min. After washing, standards and samples were incubated in 100 l of buffer B for 30 min at room temperature. Plates were washed with buffer A and anti-SHP-1 polyclonal antibody was added at 5 g/ml in buffer B, and incubated for 30 min at room temperature. HRP-labeled goat anti-rabbit IgG (GARPO) was added after washing, using a dilution of 1/2000, for 30 min at room temperature. For the detection, 100 l of a substrate solution containing 10 mM OPD, 3 mM H 2 O 2 , in 0.1 M sodium citrate was used. After 10 min at room temperature, the reaction was stopped with 100 l of 1 N H 2 SO 4 , and the color read at 492 nm in a multichannel photometer.
Results
Standardization of SHP-1 ELISA
Standard curve for mouse recombinant SHP-1 and human native SHP-1: Figure 1a and b show the standard curves obtained when increasing amounts of native SHP-1 and recombinant SHP-1 were added to each well in a range from 0.26 to 5.3 ng. Similar results, insofar as sensitivity and linearity of the assay are concerned, were obtained with human SHP-1 when compared with recombinant mouse SHP-1, both estimated about 0.5 ng per well, with a linear range between 0.25 and 4 ng. Insert in Figure 1b shows the signal obtained when increasing amounts of recombinant SHP-1 were loaded on to SDS-PAGE and immunodetected by Western blot using the ECL detection system. As can be seen, the ELISA method has a higher sensitivity. 
Correlation between recombinant and native SHP-1:
In order to ascertain if a recombinant mouse SHP-1 could be used as a standard for the quantification of human native SHP-1, both proteins have been used as standards. As shown in Figure 1c , a correlation coefficient of R ϭ 0.99 was obtained, indicating that the affinity of the antibodies was similar for both sources of SHP-1, and that the mouse recombinant protein can be used as a standard for the quantification of mouse or human SHP-1.
SHP-1 expression in HUT-78
Phenotypic characterization of HUT-78 by flow cytometry: HUT-78 is a CD4 + cutaneous lymphoma T cell line derived from a patient with Sezary syndrome. Table 1 shows the surface expression of different receptors, correceptors, and activating molecules, assessed by flow cytometry, in order to monitor the changes induced by different activating stimuli, and to compare its phenotype with the stage of the patients' malignancies. The same was done with a Jurkat T cell line, derived from a patient with acute T cell leukemia, which was used as a SHP-1-positive control CD4
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+ T cell line.
Undetectable SHP-1 protein in HUT-78 by ELISA:
As shown in Figure 2 , intracellular SHP-1 protein level in HUT-
Figure 2
Kinetics of SHP-1 protein expression in Jurkat (a) and HUT-78 (b). Cells were stimulated with 25 g/ml PHA and 5 ng/ml IL-2, or 10 ng/ml PMA and 0.1 g/ml Io, or 5 ng/ml IL-15, and harvested at the indicated times after stimulation. Cells were counted and pellets solubilized in 1% NP-40 lysis buffer. Cell lysates were assayed in the sandwich ELISA for SHP-1 content.
Leukemia 78 was undetectable (under 0.25 ng/500 000 cells) either in resting state or when stimulated with PHA and IL-2 or PMA and Io for 4, 8 and 12 h. Only when stimulated for 24 h was, SHP-1 slightly induced up to 0.5 ng/500 000 cells. SHP-1 protein levels in resting Jurkat T cells were estimated in 3.5 ng/500 000 cells, and remained unchanged under activation conditions. Additionally, IL-15 (which has been described as a major trophic factor to establish a Sezary cell line 26 had no apparent effect on SHP-1 expression in HUT-78.
Undetectable SHP-1 in HUT-78 by immunoprecipitation and Western blot:
The lack of SHP-1 protein in HUT-78 was also assessed by immunoprecipitation (IP). Figure 3 shows that SHP-1 protein was undetectable in resting HUT-78 and confirms its absence at short stimulation periods (10 min and 4 h with PMA and Io) (top line), according to ELISA data. JAK-3 was present in both Jurkat and Hut78 T cell lines (Figure 3 , bottom line).
Low but inducible transcription of SHP-1 mRNA in HUT-78:
To analyze whether the lack of SHP-1 protein expression resulted from a deficient gene transcription or protein translation we analyzed for SHP-1 mRNA expression levels in both T cell lines. Northern blot analysis showed that resting HUT-78 failed to express SHP-1 mRNA (Figure 4a ). To determine whether SHP-1 mRNA could be induced in HUT-78, we cultured the cells with PMA and Io or PHA and IL-2 for 4 or 12 h. A faint band corresponding to SHP-1 was detected when cells were stimulated with PMA and Io for 12 h, demonstrating that HUT-78 has the capacity for SHP-1 gene transcription. At a shorter stimulation time (4 h), SHP-1 mRNA could not be detected by Northern blot. However, it was detectable by RT-PCR amplification at resting conditions (Figure 4b ), supporting the existence of SHP-1 transcriptional activity.
Increased JAK3 tyrosine phosphorylation in HUT-78 vs Jurkat T cells
To explore the relationship between SHP-1 expression and tyrosine-phosphorylation of JAK3 in our HUT-78/Jurkat system, we immunoprecipitated JAK3 from both cell lines and analyzed its state of tyrosine phosphorylation. Figure 5a shows that JAK3 is more tyrosine-phosphorylated in HUT-78 than in Jurkat cell line, in resting culture conditions. We also checked for SHP-1 and JAK3 protein content and the level of tyrosine phosphorylation of JAK3 in blots of lysates from resting cells and cells treated with anti-CD3 plus IL-2, that signals through the IL-2R/JAK pathway. Figure 5b suggests that JAK3 seems to be more phosphorylated on tyrosine in resting HUT-78 cells than in Jurkat cell lysates, since a coincident band of similar molecular weight (MW) is detected for anti-phosphotyrosine (anti-PTyr) and anti-JAK3 blots. This basal phosphorylation of the putative JAK3 band on the HUT-78 cell lysates anti-PTyr blot is slightly increased under TCR plus IL-2 trigger, which seems indicative of a functional and inducible JAK3 activation pathway. In contrast, Jurkat T cells appear to have a low basal tyrosine phosphorylation of JAK3 since no phosphorylated band of equivalent MW was detected on the anti-PTyr blot of the cell lysates, and with a lower capacity of induction of phosphorylation upon TCR plus IL-2 stimulation. In resting conditions, JAK3 in PBL was not apparently tyrosine phosphorylated. These results suggest that there could be a relationship between the lack of SHP-1 protein expression and JAK3 phosphorylation in the HUT-78 Sezary T cell line.
Low or undetectable SHP-1 expression in freshly isolated T cells from patients with Sezary syndrome
To address whether SHP-1 was also decreased in SS patients, we quantified SHP-1 protein by ELISA in freshly isolated T lymphocytes from three SS patients. The normal range of SHP-1 concentration in PBLs from healthy controls was established in 5.9 Ϯ 0.8 ng per 10 6 cells (X Ϯ 2 s.d., n ϭ25), with no significant SHP-1 induction when stimulated with PMA up to 24 h. Quantification of SHP-1 in purified T and B cells was of 4.4 Ϯ 0.2 and 5.1 Ϯ 0.4 ng per 10 6 cells, respectively. As shown in Table 2 , SHP-1 was undetectable in T cells isolated from two of the patients (SS-1, SS-3) and was scarcely expressed (1 ng/10 6 T cells) in patient SS-2, with 50% of CD4 +
CD7
Ϫ T cells. Stimulation with 10 ng/ml PMA and 100 ng/ml Io for 6 h. in patients SS-1 and SS-2 did not modify these results.
In a further attempt to study SHP-1 expression, CD4 + T cells from patient SS-3 were expanded in vitro with 5 ng/ml IL-2 for 2 weeks (Figure 6a, upper histogram) , with a certain preferential expansion of CD7 + T cells with respect to their initial 
+ in the culture vs 24% initially). The CD7 Ϫ and CD7 + T cell fractions were separated by immunoselection with magnetic beads coated with anti-CD7 mAb (Figure 6a , lower histograms), and further kept on culture for another 2 weeks in the same conditions. After this second culture period, SHP-1 could be detected by Western blot in the CD4 +
+ fraction (Figure 6b ). This is probably due to an enrichment for this fraction, minority in the unfractionated CD4 + cells initially isolated from patient SS-3 (24% CD7 + and 76% CD7 Ϫ ). The CD7 Ϫ fraction, by contrast, did not expand. This might be the reason for the lower JAK3 content detected by immuno-blotting in CD7 Ϫ cells. Finally, the expression of SHP-1 mRNA was studied in patient SS-1, in whom no SHP-1 protein could be detected, either by Western blot or by ELISA. Although mRNA was not detected by Northern blot analysis, we were able to amplify SHP-1 mRNA by using RT-PCR, reflecting the existence of transcriptional activity of SHP-1 gene (Figure 4b ). However, in contrast to the HUT-78 cell line, contaminating normal PBMC cannot be absolutely discarded after the immunomagnetic process of selection of the patient's Sezary cells.
Discussion
This study shows the nearly undetectable expression of SHP-1 in freshly isolated Sezary cells and in the HUT-78 cell line, associated with an increased basal tyrosine phosphorylation of JAK3 in the HUT-78 Sezary cell line.
In order to precisely quantify SHP-1 protein content, we established a highly sensitive ELISA test. We determined SHP-1 under different stimulating conditions, to check whether it could be induced under cell activation. Previous studies in SHP-1-deficient B cell lines show that SHP-1 expression can be modulated by stimulation with phorbol ester (PMA). 18 In contrast, a similar stimulation failed to revert SHP-1 expression in some SHP-1-deficient T cell lymphoma lines, indicating either structural abnormalities of the SHP-1 gene due to methylation of the SHP-1 promoter, 20 or a lack of SHP-1 mRNA splicing in certain T cell lymphomas and myeloid leukemias. 27 Our finding of low mRNA SHP-1 content, not only in HUT-78 but also in SS patients, would be compatible with a functional in vivo blockade of gene transcription or mRNA instability.
The undetectable level of SHP-1 protein in HUT78 was associated with an increased basal tyrosine phosphorylation of JAK3. These results agree with others previously described in cutaneous T cell lymphoma lines by Zhang et al, 20, 21 where three T cell lines (PB-1, PB-2A and PB-B) were derived from a single patient with anaplasic large cell lymphoma (ALCL) at different stages of the disease. PB-2A and 2B lines showed constitutive JAK3 tyrosine phosphorylation with no detectable SHP-1 expression and represented a highly aggressive stage of the lymphoma. PB-1 was obtained at an earlier stage of lymphoma progression and showed a decreased, but detectable SHP-1 expression, that seems to be able to regulate the basal constitutive JAK3 tyrosine phosphorylation. Extrapolating, HUT-78 might represent an intermediate malignant stage of SS, since SHP-1 was undetectable but a functional capacity of signal through IL2-R was still preserved.
Recent reports demonstrate that SHP-1 is down-regulated in many HTLV-I transformed 11 and ALCL 20 lymphoma lines, in which a constitutive tyrosine phosphorylation of JAK3 is observed. Lack of SHP-1 expression also correlated with an IL-2-independent growth of these lines. When HTLV-I infected PBL clones were analyzed, the transition from IL-2-dependent to IL-2-independent paralleled with JAK activation and SHP-1 down-regulation. 11 This might be indicating a progressive loss of SHP-1 expression that could represent a critical event in the oncogenic transformation. In contrast with these results obtained with T cell lines, none of the uncultured malignant cells isolated from three patients with adult T cell leukemia/lymphoma (ATLL) 28 showed a down-regulated SHP-1 or a hyper-activated IL-2R/JAK3 pathway.
Regarding SS, the way that SHP-1 expression is correlated with lymphoma progression from CTCL to SS in vivo is presently unknown. Zhang et al 21 referred an increase in basal tyrosine phosphorylation of JAK3 in 10 out of 14 SS patients, and Brender et al 29 described a JAK/STAT activation state with a constitutive expression of suppressors of cytokine signaling proteins (SOCS-3) in cells directly isolated from one (out of three) patient with SS. These data are consistent with our findings of a down-regulated SHP-1 expression in Sezary cells.
Although a more extensive series is needed, we have noticed an inverse correlation between SHP-1 expression on T cells and the size of the leukemic CD4 +
CD7
Ϫ aberrant cell subset (SS cells). This malignant fraction comprised over 75% of the lymphoid CD4 + T cells in patients SS-1 and SS-3, in whom SHP-1 was undetected. In patient SS-2, who had a decreased expression of SHP-1, the percentage of Sezary cells was, at least that of aberrant CD4 +
Ϫ cells (49% of T cells), but it cannot be ruled out that CD4 +
+ cells were also malignant. It is noticeable that although no SHP-1 was detected in freshly isolated T cells from patient SS-3, with a majority of aberrant CD7 Ϫ cells (76%), it became detectable in the separated CD7 + fraction after IL-2 in vitro culture. We cannot rule out whether the presence of SHP-1 in the CD4 +
+ cultured fraction is due to: (1) that this fraction represented a non-malignant T cell growth, with a preserved expression of SHP-1; (2) that alternatively, these CD7 + cells could represent transformed cells with a lower grade of malignancy but they did not express, or expressed less than normal SHP-1 in vivo. Then, the IL-2 culture could have induced the expression of SHP-1. If this was the case, the absence of SHP-1 in the cultured CD7
Ϫ fraction could be due to: (1) a sensitivity problem since there were less CD7 Ϫ cells in the lysate (lower expansion in culture); (2) a true absence of SHP-1 due to their malignant condition. A possible scenario that emerges from these experiments is that of SHP-1 down-regulation in SS, to an extent proportional to the malignancy of the cell affected. Interestingly, IL-2R (CD25) expression was variable (63% of the CD4 + CD7 Ϫ cells in patient SS-1 vs negative in patient SS-3) and not apparently related with SHP-1 levels, which could be indicative of different stages in the oncogenic transformation.
In summary, in this study we report that freshly isolated Sezary cells have decreased or undetectable levels of SHP-1, as is the case for the HUT-78 Sezary line. These findings suggest the involvement of SHP-1 in the pathogenesis of Sezary syndrome.
